United Therapeutics (UTHR) Stock: Buy, Sell, or Hold?
$595.66
+7.05 (+1.20%)
▲
5d:
-2.11%
30d:
+9.62%
90d:
+18.83%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect UTHR Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (61%)
Quality Score
52/100
Position
EXTENDED
30-Day Fair Range
$543.53 – $592.84
Position: EXTENDED
Forward P/E & Valuation
18.9x
FAIR
vs 17.3x historical avg
Wall Street Target
$687.14
+15.4% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$556.63 / $614.23
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: UTHR shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1062.68
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$659.84
9.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $595.66, which is considered extended relative to its 30-day fair value range of $543.53 to $592.84. The stock's valuation (Forward PE: 18.9) is in line with its historical norms (17.3). At these levels, the market is pricing in 2.9% annual earnings growth.
Technical Outlook: Technically, UTHR is in a uptrend. Immediate support is located at $556.63, while resistance sits at $614.23.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $687.14 (+15.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UTHR is in a uptrend. Immediate support is located at $556.63, while resistance sits at $614.23.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $687.14 (+15.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$543.53 -
$592.84
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.2%
Trading Range & Key Levels
30-Day Trading Range
$543.53 -
$592.84
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$23.82
(4.0%)
Support Level
$556.63
Resistance Level
$614.23
Current Trend
Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding UTHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($687.14)
- BULLISH: Expecting earnings turnaround to 2.9% growth with 4.1% revenue growth
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
18.88
Wall Street Target
$687.14
(+15.4%)
Revenue Growth (YoY)
4.1%
Earnings Growth (YoY)
-20.3%
Profit Margin
38.6%
Valuation Premium vs History
+2.9% premium
PE vs Historical
18.9 vs 17.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$612.93
(+3%)
2-Year Target
$630.71
(+6%)
3-Year Target
$649.00
(+9%)
3-Yr Target (if PE normalizes)
(PE: 19→17)
PE COMPRESSION
$594.57
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 27.4%)
$1295.92
(+118%)
Base:
(SPY PE: 18.9, Growth: 27.4%)
$1232.22
(+107%)
Bear:
(PE: 16.1, Growth: 27.4%)
$1047.38
(+76%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 22.22 | Current EPS (TTM): $26.49
Bull Case
$770.99
(+29%)
Analyst growth 19.1%, PE expands to 24.4
Base Case
$700.90
(+18%)
Market implied 19.1%, PE stable at 22.2
Bear Case
$400.26
(-33%)
Severe decline -20.0%, PE contracts to 18.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share UTHR Analysis
Share this live UTHR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (UTHR)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Liquidia reported a 31% sequential increase in third-quarter YUTREPIA sales, with more than 70% of prescriptions being for pulmonary arterial hypertension. The company expects referrals to recover after communicating with prescribers about the settlement.
Key Retail Themes:
sales growth
product development
competitor dynamics
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 6:53 AM ET
Data refreshes hourly during market hours. Next update: 7:53 AM
Data refreshes hourly during market hours. Next update: 7:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 34 SELL |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive UTHR Research Pages
